P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies	B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, high grade B-cell lymphoma, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm	Active, not recruiting	Phase 1	2026-05-07		NCT06014762

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Poseida Therapeutics, Inc.	4
Roche-Genentech	11

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Advent Health Orlando	Orlando	United States	12
Baylor Scott & White Research Institute	Dallas	United States	15
Cedars-Sinai Medical Center	Los Angeles	United States	392
Indiana University	Indianapolis	United States	160
Loma Linda University Cancer Center	Loma Linda	United States	4
NYU Grossman School of Medicine	New York	United States	11
Ochsner Clinic Foundation	New Orleans	United States	69
Oregon Health & Science University	Portland	United States	261
Our Lady of The Lake Hospital	Baton Rouge	United States	6
Pennsylvania State University	Hershey	United States	9
Prisma Health - Upstate Cancer Institute	Greenville	United States	1
UNC Lineberger Comprehensive Cancer Center	Chapel Hill	United States	243
University of Cincinnati	Cincinnati	United States	1
University of Oklahoma, Health Sciences Center	Oklahoma City	United States	2
Vanderbilt University Medical Center	Nashville	United States	427
Wayne State - Karmanos Cancer Institute	Detroit	United States	3